Methods of Administering Amantadine
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 61/836,082, filed Jun 17, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,646,456 | Methods of Administering Amantadine In force · High confidence | Adamas Pharma, LLC | In force | High confidence | ||
| US 11,903,908 | Methods of Administering Amantadine In force · High confidence | Adamas Pharma, LLC | In force | High confidence | ||
| US 10,154,971 | Methods of Administering Amantadine In force · High confidence | Adamas Pharma, LLC | In force | High confidence | ||
| Application 16/841,452 | Methods of Administering Amantadine Abandoned Abandoned Nov 17, 2020 | Adamas Pharma, LLC | Abandoned | Abandoned Nov 17, 2020 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Adamas Pharma, LLC.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.